Efficacy/Safety Study of Nebulized IVX-0142, a Novel Antiallergic Drug, in Mild Allergic Asthma

NCT00232999 Phase 2 COMPLETED

This study is designed to evaluate the effectiveness of nebulized IVX-0142, a novel anti-allergic drug, to inhibit allergen-induced airway narrowing in patients with allergic asthma and the related increased sensitivity of the airways to other substances, as well as to investigate a possible anti-inflammatory effect of the drug in the airways.

Details

Lead sponsor	Teva Branded Pharmaceutical Products R&D, Inc.
Phase	Phase 2
Status	COMPLETED
Enrolment	15
Start date	2005-10
Completion	2006-01

Conditions

• Asthma

Interventions

• Nebulized IVX-0142

Primary outcomes

• Serial lung function tests measured up to 7 hours post-allergen challenge to assess effects on early- and late-phase asthmatic reactions

Countries

Canada